The antibody specifically binds to CD38 which is capable of killing CD38+ cells through apoptosis, antibody-dependent cell-mediated cytotoxicity, and complement-dependent cytotoxicity. The antibody may be used as a medicament or in making a medicament to treat humans with a safe therapeutic dose and targets CD38+ multiple myeloma. The antibody is a humanized IgG1 clone named Hu38SB19 derived from human sources for functional assays and research use only.